# K182698: LIAISON Calprotectin, LIAISON Calprotectin Control Set, LIAISON Calprotectin Calibration Verifiers, LIAISON Q.S.E.T. Buffer, LIAISON Q.S.E.T. Device

- Pathway: 510(k) (Traditional)
- Applicant: DiaSorin, Inc.
- Decided: Dec 26, 2018 after 90 days
- Product code: NXO (Calprotectin, Fecal)
- Device class: 2
- Regulation: 21 CFR 866.5180
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 4 generations back to K954418 (1995). 8 ancestors in all.
1 later device descends from it; 1 cites it directly.
0 of 10 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- DEN060001: Phical Test, Genova Diagnostics (2006) Summary page 4.
- K141463: Liason XL1,25 Dihydroxyvitamin D; Control Set, Calibration Verifiers, DiaSorin, Inc. (2014) Summary page 8.

## Most influential descendants
- K213858: LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus (2022), 0 descendants of its own

## Indications for use
The DiaSorin LIAISON® Calprotectin assay is an in vitro diagnostic chemiluminescent immunoassay (CLIA) intended for the quantitative measurement, in human stool, of fecal calprotectin, a neutrophilic protein that is a marker of mucosal inflammation. The LIAISON® Calprotectin assay can be used as an aid in the diagnosis of inflammatory bowel diseases (IBD), specifically Crohn’s disease and ulcerative colitis, and as an aid in differentiation of IBD from irritable bowel syndrome (IBS). Test results are to be used in conjunction with information obtained from the patients’ clinical evaluation and other diagnostic procedures. The test has to be performed on the LIAISON® XL Analyzer. The DiaSorin LIAISON® Q.S.E.T. Device (Quantitative Stool Extraction and Test) is intended for use in the preparation of human stool specimens for testing in the LIAISON® Calprotectin assay.

Source page: https://510kreport.com/device/K182698
Methodology: https://510kreport.com/methodology